News

MAIA Biotechnology (MAIA) – Phase 2 Update Shows Continued Efficacy

Health
0 min read


Wednesday, November 18, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 2 THIO-101 Part C Data Updated. MAIA announced updated disease control rate (DCR) data for patients in Part C of the Phase 2 THIO-101 trial. This three-part trial tests ateganosine (previously THIO) in combination with cemiplimab (Libtayo, an anti-PD-1 checkpoint inhibitor from Regeneron) as third-line treatment for non-small cell lung cancer. Enrollment in Part C was completed in October 2026.

Additional Patients Show Continued Disease Control Rate. The data show that patients treated with ateganosine had a Disease Control Rate (DCR) of 88%, based on 38 of 43 patients, after at least one post-treatment tumor scan. This shows continued efficacy as more patients reach the first evaluation point. As discussed in our Research Note on July 9, the first group of patients after one tumor scan had a DCR of 90.5% (19 out of 21 patients). This compares with published studies reporting rates of 25% to 35% for standard chemotherapy.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy